Literature DB >> 24521828

Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma.

Jayasri G Iyer1, Barry E Storer2, Kelly G Paulson1, Bianca Lemos3, Jerri Linn Phillips4, Christopher K Bichakjian5, Nathalie Zeitouni6, Jeffrey E Gershenwald7, Vernon Sondak8, Clark C Otley9, Siegrid S Yu10, Timothy M Johnson5, Nanette J Liegeois11, David Byrd12, Arthur Sober13, Paul Nghiem14.   

Abstract

BACKGROUND: The effects of primary tumor size on nodal involvement and of number of involved nodes on survival have not, to our knowledge, been examined in a national database of Merkel cell carcinoma (MCC).
OBJECTIVE: We sought to analyze a retrospective cohort of patients with MCC from the largest US national database to assess the relationships between these clinical parameters and survival.
METHODS: A total of 8044 MCC cases in the National Cancer Data Base were analyzed.
RESULTS: There was a 14% risk of regional nodal involvement for 0.5-cm tumors that increased to 25% for 1.7-cm (median-sized) tumors and to more than 36% for tumors 6 cm or larger. The number of involved nodes was strongly predictive of survival (0 nodes, 76% 5-year relative survival; 1 node, 50%; 2 nodes, 47%; 3-5 nodes, 42%; and ≥6 nodes, 24%; P < .0001 for trend). Younger and/or male patients were more likely to undergo pathological nodal evaluation. LIMITATIONS: The National Cancer Data Base does not capture disease-specific survival. Hence, relative survival was calculated by comparing overall survival with age- and sex-matched US population data.
CONCLUSION: Pathologic nodal evaluation should be considered even for patients with small primary MCC tumors. The number of involved nodes is strongly predictive of survival and may help improve prognostic accuracy and management.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  Merkel cell carcinoma; National Cancer Data Base; average tumor size; neuroendocrine carcinoma of the skin; nodal spread; prognosis; regional node metastasis; sentinel lymph node biopsy

Mesh:

Year:  2014        PMID: 24521828      PMCID: PMC3959572          DOI: 10.1016/j.jaad.2013.11.031

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  23 in total

1.  Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system.

Authors:  Bianca D Lemos; Barry E Storer; Jayasri G Iyer; Jerri Linn Phillips; Christopher K Bichakjian; L Christine Fang; Timothy M Johnson; Nanette J Liegeois-Kwon; Clark C Otley; Kelly G Paulson; Merrick I Ross; Siegrid S Yu; Nathalie C Zeitouni; David R Byrd; Vernon K Sondak; Jeffrey E Gershenwald; Arthur J Sober; Paul Nghiem
Journal:  J Am Acad Dermatol       Date:  2010-06-19       Impact factor: 11.527

2.  Routine omission of sentinel lymph node biopsy for merkel cell carcinoma <= 1 cm is not justified.

Authors:  Amod A Sarnaik; Jonathan S Zager; L Elizabeth Cox; Tatiana M Ochoa; Jane L Messina; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

3.  Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Shouluan Ding; David R Byrd; Natale Cascinelli; Alistair J Cochran; Daniel G Coit; Alexander M Eggermont; Timothy Johnson; John M Kirkwood; Stanley P Leong; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

4.  The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

Authors:  Stephen B Edge; Carolyn C Compton
Journal:  Ann Surg Oncol       Date:  2010-06       Impact factor: 5.344

5.  Patients with clinically node negative extremity Merkel cell carcinoma: The importance of identifying and treating patients with microscopic nodal metastases.

Authors:  Michael Veness; Julie Howle
Journal:  Australas J Dermatol       Date:  2010-10-13       Impact factor: 2.875

6.  Features predicting sentinel lymph node positivity in Merkel cell carcinoma.

Authors:  Jennifer L Schwartz; Kent A Griffith; Lori Lowe; Sandra L Wong; Scott A McLean; Douglas R Fullen; Christopher D Lao; James A Hayman; Carol R Bradford; Riley S Rees; Timothy M Johnson; Christopher K Bichakjian
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

7.  Recurrence and survival in patients undergoing sentinel lymph node biopsy for merkel cell carcinoma: analysis of 153 patients from a single institution.

Authors:  Ryan C Fields; Klaus J Busam; Joanne F Chou; Katherine S Panageas; Melissa P Pulitzer; Dennis H Kraus; Mary S Brady; Daniel G Coit
Journal:  Ann Surg Oncol       Date:  2011-03-24       Impact factor: 5.344

8.  Gender differences in stomach cancer survival in Osaka, Japan: analyses using relative survival model.

Authors:  Naomi Sato; Yuri Ito; Akiko Ioka; Masahiro Tanaka; Hideaki Tsukuma
Journal:  Jpn J Clin Oncol       Date:  2009-08-17       Impact factor: 3.019

9.  Patients with Merkel cell carcinoma tumors < or = 1.0 cm in diameter are unlikely to harbor regional lymph node metastasis.

Authors:  Jayme B Stokes; Katherine S Graw; Lynn T Dengel; Brian R Swenson; Todd W Bauer; Craig L Slingluff; Elihu J Ledesma
Journal:  J Clin Oncol       Date:  2009-07-06       Impact factor: 44.544

10.  Unstaged cancer in the United States: a population-based study.

Authors:  Ray M Merrill; Arielle Sloan; Allison E Anderson; Karem Ryker
Journal:  BMC Cancer       Date:  2011-09-21       Impact factor: 4.430

View more
  25 in total

1.  Tumor vascularization and clinicopathologic parameters as prognostic factors in merkel cell carcinoma.

Authors:  A Bob; F Nielen; J Krediet; J Schmitter; D Freundt; D Terhorst; J Röwert-Huber; J Kanitakis; E Stockfleth; Ch Ulrich; M Weichenthal; F Egberts; B Lange-Asschenfeldt
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-21       Impact factor: 4.553

2.  Molecular Profiling of Multiple Primary Merkel Cell Carcinoma to Distinguish Genetically Distinct Tumors From Clonally Related Metastases.

Authors:  Kelly L Harms; Lorena Lazo de la Vega; Daniel H Hovelson; Samantha Rahrig; Andi K Cani; Chia-Jen Liu; Douglas R Fullen; Min Wang; Aleodor A Andea; Christopher K Bichakjian; Timothy M Johnson; Scott A Tomlins; Paul W Harms
Journal:  JAMA Dermatol       Date:  2017-06-01       Impact factor: 10.282

Review 3.  Secondary solid cancer screening following hematopoietic cell transplantation.

Authors:  Y Inamoto; N N Shah; B N Savani; B E Shaw; A A Abraham; I A Ahmed; G Akpek; Y Atsuta; K S Baker; G W Basak; M Bitan; Z DeFilipp; T K Gregory; H T Greinix; M Hamadani; B K Hamilton; R J Hayashi; D A Jacobsohn; R T Kamble; K A Kasow; N Khera; H M Lazarus; A K Malone; M T Lupo-Stanghellini; S P Margossian; L S Muffly; M Norkin; M Ramanathan; N Salooja; H Schoemans; J R Wingard; B Wirk; W A Wood; A Yong; C N Duncan; M E D Flowers; N S Majhail
Journal:  Bone Marrow Transplant       Date:  2015-03-30       Impact factor: 5.483

Review 4.  Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.

Authors:  Teresa Amaral; Ulrike Leiter; Claus Garbe
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

Review 5.  Sentinel lymph node biopsy for eyelid and conjunctival tumors: what is the evidence?

Authors:  Pia R Mendoza; Hans E Grossniklaus
Journal:  Int Ophthalmol Clin       Date:  2015

6.  Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients.

Authors:  C Ricci; A Righi; F Ambrosi; D Gibertoni; F Maletta; S Uccella; F Sessa; S Asioli; M Pellilli; R Maragliano; S La Rosa; M G Papotti; S Asioli
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

7.  Identifying an Optimal Adjuvant Radiotherapy Dose for Extremity and Trunk Merkel Cell Carcinoma Following Resection: An Analysis of the National Cancer Database.

Authors:  Sagar A Patel; Muhammad M Qureshi; Debjani Sahni; Minh Tam Truong
Journal:  JAMA Dermatol       Date:  2017-10-01       Impact factor: 10.282

8.  An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma.

Authors:  Adrienne B Shannon; Richard J Straker; Michael J Carr; James Sun; Karenia Landa; Kirsten Baecher; Kevin Lynch; Harrison G Bartels; Robyn Panchaud; Luke J Keele; Michael C Lowe; Craig L Slingluff; Mark J Jameson; Kenneth Y Tsai; Mark B Faries; Georgia M Beasley; Vernon K Sondak; Giorgos C Karakousis; Jonathan S Zager; John T Miura
Journal:  Ann Surg Oncol       Date:  2022-07-22       Impact factor: 4.339

Review 9.  Merkel Cell Carcinoma Therapeutic Update.

Authors:  Nicole M Cassler; Dean Merrill; Christopher K Bichakjian; Isaac Brownell
Journal:  Curr Treat Options Oncol       Date:  2016-07

10.  Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System.

Authors:  Kelly L Harms; Mark A Healy; Paul Nghiem; Arthur J Sober; Timothy M Johnson; Christopher K Bichakjian; Sandra L Wong
Journal:  Ann Surg Oncol       Date:  2016-05-19       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.